The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

Amgen (NasdaqGS:AMGN) experienced a significant 18.62% price increase over the last quarter, coinciding with the recent FDA ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment ...

Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval ...

Shares of medicine manufacturer Amgen Inc (AMGN) are in the spotlight on Friday after it announced that the U.S. Food and ...

Inebilizumab-cdon was previously approved by the FDA for neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...

Acquired as part of its $27.8 billion takeover of Horizon Therapeutics in 2023, CD19-targeting Uplizna (inebilizumab) is the ...

Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...

US FDA approves Amgen’s Uplizna to treat IgG4-related disease: Thousand Oaks, California Saturday, April 5, 2025, 11:00 Hrs [IST] Amgen announced that the US Food and Drug Admin ...

Amgen (NASDAQ:AMGN) announced today that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and onl ...